<?xml version="1.0" encoding="UTF-8"?>
<p id="p0090">Tocilizumab, a humanized monoclonal antibody, inhibits all forms of interleukin-6 (IL-6) receptors (membrane bound or soluble). Tocilizumab was first approved for rheumatoid but was later considered as a complementary treatment in cytokine-release syndrome disease (
 <xref rid="bib28" ref-type="bibr">Kotch et al., 2019</xref>). Tocilizumab can diminish the effect of cytokine storming, including IL-6, which is associated with severe outcomes in patients with COVID-19 (
 <xref rid="bib73" ref-type="bibr">Zhou et al., 2020a</xref>).
</p>
